[A20-06] Ivacaftor (combination with tezacaftor/ivacaftor, cystic fibrosis, 12 years and older, with F508del mutation, heterozygous) - Addendum to Commission A19-71
|Commission:||Commission awarded on 2020-01-07 by the Federal Joint Committee (G-BA)|
|Current document:||Addendum to commission A19-71 Further documents|
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|Contact address:||to the contact form|
Ivacaftor (combination with ivacaftor/tezacaftor, cystic fibrosis, 12 years and older, with F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
|2020-02-20||Addendum to commission A19-71||301 kB|
Federal Joint Committee (G-BA)
2020-02-20 A G-BA decision was published.